undamentalytics Newsletter
Sign in

Intellia Therapeutics, Inc. (NTLA) stock

Add to watchlist

Add holding +

NASDAQ: NTLA Nasdaq Biotechnology Next results ~November 5, 2026

D Fundamentals grade

Intellia Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$5.9

Valuation models combined (2)

Base case. Range ~$2.8–$6.6. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Intellia Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 7 selling1 purchase and 18 sales by directors and officers, last 12 monthsInsider trades
  • Funds190 adding, 107 cuttingOf 51 active managers that changed their stake, 34 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Intellia Therapeutics files

Where Intellia Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $60m, up 12.6% on a year earlier, slower than the 45.0% growth a quarter earlier. Free-cash-flow margin rose to -586.0% from -798.0% a year earlier. Operating margin widened to -711.7% from -968.7%. The diluted share count is up 16.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Intellia Therapeutics, Inc.'s trailing-twelve-month revenue grew 12.6% year on year, with a free-cash-flow margin of -586.0%.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 12.6% (-32.5pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 257.0 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Growth slowing. The growth rate is 32.5 points lower than a quarter earlier.
  • Loss-making. Operating margin is -711.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -586.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 114.1% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 16.6% in a year.
  • High sales multiple. The shares trade at 23 times revenue while operating margins remain thin.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.80 against an average estimate of -$0.78: missed by 1.9%
Revenue
$8m, down 46.2% on a year earlier
Share reaction
+8.8% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.79

Intellia Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.5%
  • 1 week+3.6%
  • 1 month-4.9%
  • This year+29.7%
  • 1 year-7.6%
  • 5 years-91.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$59.5M
Operating margin
-711.7%
Net margin
-672.2%
EPS (TTM, diluted)
$-3.35

Growth

Revenue growth
+12.6%
Change in growth rate
−32.5 pts
Share count change
+16.6%

Cash

Free cash flow (TTM)
-$349M
FCF margin
-586.0%
Stock pay % of revenue
114.1%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Agreement
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Intellia Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Intellia Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.44 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.6 ~$4.3–$8.9 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.8 ~$2.8–$11 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$5.9 ~$2.8–$6.6 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Intellia Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$13.11$19.22$13.65$14.67$54.40$118.24$34.89$30.49$11.66$8.99$11.66
Market value$291m$692m$588m$693m$3.0bn$8.4bn$2.7bn$2.7bn$1.2bn$974m$1.4bn
+ Net debt (− = net cash)−$273m−$341m−$59m−$57m−$160m−$123m−$524m−$227m−$189m−$155m−$106m
Enterprise value$18m$351m$529m$636m$2.9bn$8.3bn$2.2bn$2.5bn$963m$819m$1.3bn
Multiples
Price / sales 17.7x26.5x19.3x16.1x52.5xn/m51.5x74.6x19.9x14.4x23.4x
Price / earnings ———————————
Price / free cash flow 9.7x——————————
EV / EBITDA ———————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Intellia Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -30.9% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -711.7%; its worst year was -1140.0%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 9 years, at a median -586.0% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 87.2% over five years; stock-based pay has been a median 114.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $10m and EPS of −$0.79 (range −$0.89 to −$0.71) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.14 +18% $52m −23%
Next −$2.56 +18% $126m +143%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.1% on 90 days ago. In the last 30 days, 2 analysts raised Intellia Therapeutics, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Intellia Therapeutics, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.14 Current fiscal year, 60 days ago: −$3.15 Current fiscal year, 30 days ago: −$3.16 Current fiscal year, 7 days ago: −$3.15 Current fiscal year, Now: −$3.14 −$3.14 Next fiscal year, 90 days ago: −$1.76 Next fiscal year, 60 days ago: −$2.60 Next fiscal year, 30 days ago: −$2.60 Next fiscal year, 7 days ago: −$2.57 Next fiscal year, Now: −$2.56 −$2.56

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.14−$1.76
60 days ago −$3.15−$2.60
30 days ago −$3.16−$2.60
7 days ago −$3.15−$2.57
Now −$3.14−$2.56

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.78 −$0.80 −1.9%
Mar 2026 −$0.90 −$0.81 +9.8%
Dec 2025 −$0.96 −$0.83 +13.7%
Sept 2025 −$0.98 −$0.92 +6.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

20 analysts, Oct 2026
Buy1050%
Hold630%
Sell420%

Monthly trend

  1. Oct 2026962220
  2. Sep 202696219
  3. Aug 202696219
  4. Jul 202687219

Counts of recommendations published by analysts covering Intellia Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
40.0%
of tradable shares
Days to cover
7.63
at average volume
Short interest, 1 month
−5%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
3.8%
of shares
Employees
377
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −7.6%

$12.62 on October 31, 2025 to $11.66

ThenNowEffect
Revenue (last 12 months) $53m $60m +12.6%
P/S multiple 24.5x 23.4x −4.3%
Share count 103m 120m −14.2%

Biggest factor: share count. Loss-making at one end, so the split uses price/sales.

Last 3 years −59.5%

$28.76 on November 3, 2023 to $11.66

ThenNowEffect
Revenue (last 12 months) $53m $60m +12.2%
P/S multiple 45.2x 23.4x −48.1%
Share count 83m 120m −30.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NTLA+117%−71%−13%−62%−23%+30%
Industry peers (median)−36%−56%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NTLA42%25%50%33%33%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NTLA−44%−72%−50%−65%−71%−40%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since May 6, 2016: 96% from September 3, 2021 to April 8, 2025. Getting back needed a 2715% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$8.04 – $17.84
From 52-week high
−34.6%
vs 50-day average
−4.5%
vs 200-day average
−10.9%
Volatility (1 year)
80%
Beta vs S&P 500
2.52

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±8.3%
After a week
5 up, 7 down
typical move ±11.4%
After a month
5 up, 7 down
typical move ±13.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +8.8% +0.5% +7.8% +16.1%
May 11, 2026 −0.7% +0.1% −9.9% −13.4%
April 30, 2026 +6.5% +1.3% +10.2% +10.3%
February 26, 2026 +2.7% −1.0% −2.0% −7.8%
November 6, 2025 −29.8% −1.0% −36.1% −30.4%
August 7, 2025 −5.1% +0.7% −4.1% +4.1%
May 8, 2025 +11.4% +0.6% +10.8% +13.6%
February 27, 2025 −6.6% −0.1% −8.3% −25.3%
January 10, 2025 −16.4% −1.4% −21.0% −23.4%
November 7, 2024 +4.2% +1.2% −5.9% −9.0%
August 8, 2024 +0.7% +2.8% +7.3% −6.9%
May 9, 2024 +6.3% +0.7% +13.8% +1.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Intellia Therapeutics, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Intellia Therapeutics, Inc.
$30M $40M $50M $60M $70M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $51.8M Revenue (TTM), FY23 Q4: $36.3M Revenue (TTM), FY24 Q1: $52.6M Revenue (TTM), FY24 Q2: $46M Revenue (TTM), FY24 Q3: $43.1M Revenue (TTM), FY24 Q4: $57.9M Revenue (TTM), FY25 Q1: $45.6M Revenue (TTM), FY25 Q2: $52.9M Revenue (TTM), FY25 Q3: $57.5M Revenue (TTM), FY25 Q4: $67.7M Revenue (TTM), FY26 Q1: $66.1M Revenue (TTM), FY26 Q2: $59.5M $59.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $51.8M
FY23 Q4 $36.3M
FY24 Q1 $52.6M
FY24 Q2 $46M
FY24 Q3 $43.1M
FY24 Q4 $57.9M
FY25 Q1 $45.6M
FY25 Q2 $52.9M
FY25 Q3 $57.5M
FY25 Q4 $67.7M
FY26 Q1 $66.1M
FY26 Q2 $59.5M
Revenue growth, TTM YoY Intellia Therapeutics, Inc.
-50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 0.7% Revenue growth, TTM YoY, FY23 Q4: -30.4% Revenue growth, TTM YoY, FY24 Q1: -1.6% Revenue growth, TTM YoY, FY24 Q2: -13.3% Revenue growth, TTM YoY, FY24 Q3: -16.8% Revenue growth, TTM YoY, FY24 Q4: 59.6% Revenue growth, TTM YoY, FY25 Q1: -13.4% Revenue growth, TTM YoY, FY25 Q2: 15.0% Revenue growth, TTM YoY, FY25 Q3: 33.5% Revenue growth, TTM YoY, FY25 Q4: 16.9% Revenue growth, TTM YoY, FY26 Q1: 45.0% Revenue growth, TTM YoY, FY26 Q2: 12.6% 12.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 0.7%
FY23 Q4 -30.4%
FY24 Q1 -1.6%
FY24 Q2 -13.3%
FY24 Q3 -16.8%
FY24 Q4 59.6%
FY25 Q1 -13.4%
FY25 Q2 15.0%
FY25 Q3 33.5%
FY25 Q4 16.9%
FY26 Q1 45.0%
FY26 Q2 12.6%
Operating margin (TTM) Intellia Therapeutics, Inc.
-1500% -1000% -500% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -937.9% Operating margin (TTM), FY23 Q4: -1420.5% Operating margin (TTM), FY24 Q1: -983.5% Operating margin (TTM), FY24 Q2: -1140.0% Operating margin (TTM), FY24 Q3: -1248.0% Operating margin (TTM), FY24 Q4: -923.1% Operating margin (TTM), FY25 Q1: -1187.4% Operating margin (TTM), FY25 Q2: -968.7% Operating margin (TTM), FY25 Q3: -832.2% Operating margin (TTM), FY25 Q4: -651.7% Operating margin (TTM), FY26 Q1: -636.6% Operating margin (TTM), FY26 Q2: -711.7% -711.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -937.9%
FY23 Q4 -1420.5%
FY24 Q1 -983.5%
FY24 Q2 -1140.0%
FY24 Q3 -1248.0%
FY24 Q4 -923.1%
FY25 Q1 -1187.4%
FY25 Q2 -968.7%
FY25 Q3 -832.2%
FY25 Q4 -651.7%
FY26 Q1 -636.6%
FY26 Q2 -711.7%
FCF margin (TTM) Intellia Therapeutics, Inc.
-1500% -1000% -500% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -786.8% FCF margin (TTM), FY23 Q4: -1124.9% FCF margin (TTM), FY24 Q1: -794.8% FCF margin (TTM), FY24 Q2: -832.5% FCF margin (TTM), FY24 Q3: -842.6% FCF margin (TTM), FY24 Q4: -612.8% FCF margin (TTM), FY25 Q1: -836.4% FCF margin (TTM), FY25 Q2: -798.0% FCF margin (TTM), FY25 Q3: -717.3% FCF margin (TTM), FY25 Q4: -585.0% FCF margin (TTM), FY26 Q1: -550.2% FCF margin (TTM), FY26 Q2: -586.0% -586.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -786.8%
FY23 Q4 -1124.9%
FY24 Q1 -794.8%
FY24 Q2 -832.5%
FY24 Q3 -842.6%
FY24 Q4 -612.8%
FY25 Q1 -836.4%
FY25 Q2 -798.0%
FY25 Q3 -717.3%
FY25 Q4 -585.0%
FY26 Q1 -550.2%
FY26 Q2 -586.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 16 26 30 43 58 33 52 36 58 68 60
Gross profit — — 30 43 58 33 — — — — —
EBITDA −31 −67 −86 −101 −130 −261 −451 −506 −524 −431 −414
Operating income −32 −70 −91 −106 −137 −268 −458 −515 −534 −441 −423
Net income −32 −68 −85 −474 −134 −268 −474 −481 −519 −413 −400
Diluted EPS −$1.42 −$1.88 −$1.98 −$2.11 −$2.40 −$3.78 −$6.16 −$5.42 −$5.25 −$3.81 −$3.35
Growth (year on year)
Revenue — +58.5% +16.5% +41.6% +34.5% −43.0% +57.7% −30.4% +59.6% +16.9% +12.6%
Margins
Gross margin — — 100.0% 100.0% 100.0% 100.0% — — — — —
EBITDA margin −188.5% −254.9% −283.9% −233.8% −224.6% −789.5% −864.5% <−999% −905.3% −637.2% −696.4%
Operating margin −195.2% −266.3% −298.6% −246.8% −235.5% −810.4% −879.0% <−999% −923.1% −651.7% −711.7%
Net margin −192.0% −258.6% −280.4% <−999% −231.5% −810.5% −909.8% <−999% −896.8% −609.9% −672.2%
Free-cash-flow margin 181.7% −288.6% −222.2% −255.3% −92.2% −719.4% −665.5% <−999% −612.8% −585.0% −586.0%
Cash flow
Cash from operations 36 −65 −61 −103 −50 −225 −333 −394 −349 −395 −347
Capital spending 6 10 6 7 4 13 14 14 6 1 2
Free cash flow 30 −75 −68 −110 −53 −238 −347 −408 −355 −396 −349
Stock-based pay 7 15 17 15 20 47 91 134 154 80 68
Free cash flow after stock pay 23 −91 −85 −125 −73 −285 −438 −542 −509 −476 −417
Balance sheet
Cash 273 341 59 57 160 123 524 227 189 155 106
Total debt 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −273 −341 −59 −57 −160 −123 −524 −227 −189 −155 −106
Diluted shares 22m 36m 43m 47m 56m 71m 77m 89m 99m 108m 120m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $857m
Short-term assets $528mLonger-term assets $329m
What it owes, and who funded it · $857m
Short-term liabilities $79mLonger-term liabilities $50mShareholders' equity $728m
  • Short-term assets cover short-term liabilities $528m of assets due within a year against $79m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $528m short-term assets against $50m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Intellia Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+16.6%
year over year
R&D spending
582.7%
of revenue
Days sales outstanding
45 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated NTLA FENC IVVD CUVL NKTR TNGX Median
Revenue, last 12 months $60m $59m $58m $64m $55m $54m $56m
Revenue growth, last 12 months 12.6% 77.8% 26.3% 5.2% −27.2% 121.5% 12.6%
Revenue growth, 3-year average 3.9% 566.5% — — −14.6% 16.9% 13.7%
Revenue growth, latest quarter −46.2% 85.2% 21.2% — −9.3% −100.0% 10.2%
Gross margin 100.0% 94.1% — 82.9% 100.0% — 82.9%
Operating margin −711.7% −1.9% −192.8% 43.4% −257.8% −253.4% −189.4%
Operating margin, 3-year average −940.1% −6.3% <−999% — −189.3% −404.1% −363.5%
Net margin −672.2% −5.5% −183.9% 36.0% −287.8% −229.9% −169.8%
Cash from operations / revenue −582.5% −3.4% −185.8% 20.1% −428.3% −267.4% −168.0%
Free-cash-flow margin −586.0% −3.4% −187.9% 18.4% −428.7% −268.1% −162.4%
Free-cash-flow margin, 3-year average −738.8% 2.9% <−999% — −288.4% −388.7% −310.0%
Stock pay / revenue 114.1% 12.7% 19.2% 2.5% 22.0% 74.9% 20.0%
Change in share count 16.6% 23.6% 14.0% 0.7% 6.2% 21.8% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 12.6% 12.6% 86 of 172
Change in growth rate Growth -32.5pp -0.1pp 134 of 172
Operating margin Profitability -711.7% -189.4% 130 of 175
Net margin Profitability -672.2% -157.3% 134 of 180
Free-cash-flow margin Cash generation -586.0% -145.4% 132 of 176
Stock pay as % of revenue Cash generation 114.1% 19.2% 138 of 179
Change in share count Balance sheet 16.6% 7.9% 110 of 156
Days sales outstanding Balance sheet 45 days 75 days 24 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$2.4B
Institutions reporting
326
Shares held vs prior quarter
▲ 30.2%
Positions opened / closed
50 / 28

Top buyers and sellers, Q2 2026: 190 institutions bought and 107 sold ; the biggest buyer was RA Capital Management, L.P (+4.5M shares) and the biggest seller UBS Group AG (−537K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
ARK Investment Management LLC $286M 16.9M 11.7% ▲ 16.3%
Blackrock, Inc. $261M 15.4M 10.7% ▲ 26.8%
State Street Corp $156M 9.2M 6.4% ▲ 33.4%
Vanguard Portfolio Management LLC $124M 7.3M 5.1% ▲ 17.8%
D. E. Shaw & Co., Inc. $109M 6.4M 4.5% ▲ 12.5%
Vanguard Capital Management LLC $102M 6.0M 4.2% ▲ 18.6%
Two Sigma Investments, LP $88.6M 5.2M 3.6% ▲ 11.3%
FMR LLC $80.8M 4.8M 3.3% ▲ 130.9%
RA Capital Management, L.P. $76.6M 4.5M 3.1% New
Regeneron Pharmaceuticals, Inc. $62.7M 3.7M 2.6% 0.0%
Geode Capital Management, LLC $61.4M 3.6M 2.5% ▲ 27.3%
Arrowstreet Capital, Limited Partnership $55.5M 3.3M 2.3% ▲ 134.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Intellia Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 5 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $1.4M 1 trade by 1 insider, last 12 months Insider sales History → $2.2M 18 trades by 7 insiders · 56% under pre-set plans
Net ▼ $760,814 net selling
Insider Date Trade Shares Price Value
Dube Michael P VP, Chief Accounting Officer October 2, 2026 Sell 1,864 $12.43 $23,170
Leonard John M President and CEO August 21, 2026 Sell pre-set plan 2,785 $13.00 $36,205
Leonard John M President and CEO August 20, 2026 Sell pre-set plan 19,890 $12.60 $250,614
Dulac Edward J Iii EVP, Chief Financial Officer July 22, 2026 Sell 8,111 $11.25 $91,249
Dulac Edward J Iii EVP, Chief Financial Officer July 2, 2026 Sell pre-set plan 4,677 $18.00 $84,186
Dube Michael P VP, Chief Accounting Officer July 1, 2026 Sell 2,641 $16.78 $44,316
Clark Eliana EVP, Chief Technical Officer March 2, 2026 Sell 607 $13.78 $8,364
Basta James EVP, General Counsel March 2, 2026 Sell 1,211 $13.78 $16,688
Dube Michael P VP, Chief Accounting Officer January 5, 2026 Sell 2,989 $9.21 $27,529
Dulac Edward J Iii EVP, Chief Financial Officer January 5, 2026 Sell 6,379 $9.21 $58,751
Clark Eliana EVP, Chief Technical Officer January 5, 2026 Sell 9,515 $9.21 $87,633
Lebwohl David EVP, Chief Medical Officer January 5, 2026 Sell 11,903 $9.21 $109,627

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 10 trades and filings

No trades in Intellia Therapeutics, Inc. disclosed in the last 12 months; 10 earlier trades on record.

  • Donald S. Beyer, Jr.(D-VA 8):Sale (full), $15,001 - $50,000, traded February 28, 2022, filed March 3, 2022
  • Donald S. Beyer, Jr.(D-VA 8):Sale (full), $1,001 - $15,000, traded October 29, 2021, filed October 30, 2021
  • Donald S. Beyer, Jr.(D-VA 8):Sale (full), $1,001 - $15,000, traded September 20, 2021, filed October 1, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 23, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 11, 2026
  • April 30, 2026
  • February 26, 2026
  • November 6, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on Intellia Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Intellia Therapeutics, Inc. in brief

What does Intellia Therapeutics, Inc. do?
Intellia Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Intellia Therapeutics, Inc.'s stock ticker?
Intellia Therapeutics, Inc. trades under the ticker NTLA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Intellia Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Intellia Therapeutics, Inc. reported revenue of $59.5M, 12.6% higher than a year earlier, according to its SEC filings.
What is Intellia Therapeutics, Inc.'s free cash flow?
Intellia Therapeutics, Inc.'s free-cash-flow margin is -586.0% of revenue over the trailing twelve months, ranking 132 of the 176 biotechnology companies we cover.
Who are Intellia Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are ARK Investment Management LLC, Blackrock, Inc. and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Intellia Therapeutics, Inc.'s market cap?
On November 2, 2026, Intellia Therapeutics, Inc.'s market capitalisation was about $1.4B and net debt of -$106M. Market figures come from third-party market data and may be delayed.
Who are Intellia Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Intellia Therapeutics, Inc. are Fennec Pharmaceuticals Inc., Invivyd, Inc., Clinuvel Pharmaceuticals Ltd, Nektar Therapeutics and Tango Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Intellia Therapeutics, Inc.'s.
Are insiders buying or selling Intellia Therapeutics, Inc. stock?
Over the last 12 months, Intellia Therapeutics, Inc.'s directors and officers reported 1 open-market purchases and 18 sales on Form 4. The insider trading page charts every trade.
When is Intellia Therapeutics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Intellia Therapeutics, Inc. announces its own schedule.